Treatment and Prognosis for Metastatic Prostate Adenocarcinoma

Immediate First-Line Treatment

The European Society for Medical Oncology recommends continuous androgen deprivation therapy (ADT) combined with docetaxel chemotherapy as the first-line treatment for fit patients with metastatic hormone-naïve prostate cancer with bone metastases 1, 2.
ADT should be achieved through either bilateral orchiectomy or LHRH agonist/antagonist therapy, with a short-course antiandrogen administered to prevent disease flare from the initial testosterone surge 2.
Docetaxel should be given at 75 mg/m² every 3 weeks for patients fit enough for chemotherapy, with alternative first-line options including ADT plus novel hormone agents for patients who cannot tolerate chemotherapy 1, 3, 4.

The American College of Radiology recommends that all patients with bone metastases receive bone-protective agents to prevent skeletal-related events (SREs), with denosumab 120 mg subcutaneously every 4 weeks being superior to zoledronic acid in delaying SREs (HR 0.82, P=0.0002) 1, 2.
Alternative bone-protective agents include zoledronic acid 4 mg intravenously every 3-4 weeks, with neither agent improving overall survival but both preventing pathologic fractures, spinal cord compression, and need for bone surgery or radiation 1, 2.

The National Comprehensive Cancer Network recommends a single 8 Gy fraction of external beam radiation for painful bone metastases in the pelvis or ribs, providing equivalent pain relief to multi-fraction regimens 1, 2.
Single-fraction treatment is more convenient and cost-effective than 10 fractions of 3 Gy (30 Gy total), with radiation reserved for symptomatic sites or impending pathologic fractures 2, 3.

The European Association of Urology recommends implementing spine surveillance and metabolic monitoring from treatment initiation, with MRI of the spine to detect subclinical cord compression in all patients with vertebral metastases 1, 2.
Patients should be monitored for bone densitometry for osteoporosis, metabolic syndrome complications, and cardiovascular risk factors, with regular exercise recommended to reduce fatigue and improve quality of life 1, 2.

The American College of Radiology recommends that treatment escalation follows a specific sequence when disease progresses despite castrate testosterone levels, with first-line options including abiraterone or enzalutamide for asymptomatic/mildly symptomatic castration-resistant prostate cancer (CRPC) 1, 4, 5.
For symptomatic CRPC, docetaxel 75 mg/m² every 3 weeks remains the standard chemotherapy, with post-docetaxel options including cabazitaxel, enzalutamide or abiraterone, radium-223, and 177Lu-PSMA-617 for PSMA-expressing tumors 1, 3, 4, 6, 7.

The American College of Radiology states that median survival for metastatic castration-resistant prostate cancer is less than 2 years, with time to castration resistance averaging 14-30 months from ADT initiation 5.
More than 90% of CRPC patients have bone metastases, with prognosis improving with early aggressive combination therapy (ADT + docetaxel or novel hormones) in the hormone-sensitive phase 1, 4, 5, 6.

Short‑course anti‑androgen prophylaxis – When starting a luteinizing‑hormone‑releasing hormone (LHRH) agonist, give a 4‑week anti‑androgen (e.g., bicalutamide) to prevent a testosterone‑surge flare. Level II evidence (NCCN). 8

Abiraterone + prednisone or enzalutamide combined with ADT – Adding either agent to continuous ADT improves overall survival in metastatic hormone‑sensitive disease and has a favorable benefit‑harm profile. Level I evidence (Phase III trials). 9
Preference for hormonal intensification over chemotherapy in patients ≥85 years – Novel androgen‑receptor pathway inhibitors provide comparable efficacy with better tolerability than docetaxel in older adults. Level I evidence (clinical trial subgroup analyses). 9

Zoledronic acid as an alternative – If denosumab cannot be used, administer zoledronic acid 4 mg intravenously every 3–4 weeks for skeletal‑related event (SRE) prophylaxis. Level II evidence (NCCN recommendation). 8

Switch between abiraterone and enzalutamide – Upon castration‑resistant progression after one AR‑targeted agent, the other may be used, acknowledging a high likelihood of cross‑resistance. Level III evidence (retrospective analyses). 9
Cabazitaxel after docetaxel failure – Cabazitaxel is indicated for patients who progress following docetaxel, but carries substantial toxicity in the elderly. Level I evidence (TROPIC trial). 9
Radium‑223 for bone‑predominant CRPC without visceral disease – Six monthly doses (55 kBq/kg) improve overall survival by ≈3.6 months and reduce skeletal events. Level I evidence (ALSYMPCA trial). 9

Serial PSA and imaging – Obtain a baseline PSA at ADT start, then repeat every 3–6 months with periodic conventional imaging to assess disease response. Level III evidence (guideline consensus). 10

Do not exclude chemotherapy solely on chronological age – Functional status, comorbidities, and patient preferences should guide eligibility. Level III evidence (expert opinion).
Novel hormonal agents are preferred for tolerability – In patients ≥85 years, abiraterone or enzalutamide are favored over docetaxel when performance status permits. Level I evidence (clinical trial data). 9